•  
  •  
  •  
  •  

2026-03-27 08:04:37

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • EaseMyTrip Enters Exclusive Partnership with MSTC Ltd. to Power Travel Services for Govt Sector
  • Sundaram-Clayton Completes Rs 558.62 Cr Land Sale
  • 3i Infotech Digital BPS Ltd receives order from Mahanagar Gas Ltd
  • AZAD Engineering Ltd signs long term contract with Mitsubishi Heavy Industries Ltd
  • PNGS Gargi Fashion Jewellery Ltd opens new store in Pune

Keywords Selected:  Capsules

Stock Report

  • Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg
  • Natural Biogenex and Fermbox Bio Enter Strategic Framework and Manufacturing Agreements to Strengthen Fermentation-Based CDMO Capabilities
  • Eugia Pharma announces launch of Pomalidomide Capsules in the US
  • NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst&®) in the U.S. market
  • Department of Drug Controller directs Natural Capsules Ltd to close operations of plant
  • Shelter Pharma Limited Launches D3 Cure Capsules
  • ZIM Laboratories Ltd receives approval from CDSCO - Directorate General of Health Services for Naproxen + Esomeprazole Capsules
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Lupin receives approval from U.S. FDA for Lenalidomide Capsules
  • Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
  • Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg
  • Aayush Wellness Ltd launches Brain Fuel Capsules
  • Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg
  • Strides strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg
  • ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg
  • Zydus receives final approval from USFDA for Enzalutamide Capsules, 40 mg
  • Zydus receives final approval from USFDA for Amantadine extended-release capsules 68.5 mg and tentative approval for 137 mg
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg

Latest Post

  • EaseMyTrip Enters Exclusive Partnership with MSTC Ltd. to Power Travel Services for Govt Sector
  • Sundaram-Clayton Completes Rs 558.62 Cr Land Sale
  • 3i Infotech Digital BPS Ltd receives order from Mahanagar Gas Ltd
  • AZAD Engineering Ltd signs long term contract with Mitsubishi Heavy Industries Ltd
  • PNGS Gargi Fashion Jewellery Ltd opens new store in Pune


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025